- Efficacy and safety of adjuvant ensartinib in stage I ALK-positive NSCLC patients: a retrospective, multicenter study. [Journal Article]Lung Cancer. 2026 Oct 09; 222:109649. [Online ahead of print]LC
- CONCLUSIONS: Exploratory analyses suggested an association between adjuvant ensartinib and favorable DFS outcomes in stage I ALK-positive NSCLC patients exhibiting high-risk pathological features. A favorable safety profile was also observed. For patients without high-risk factors, the benefit of adjuvant ensartinib remains to be further clarified. These findings are hypothesis-generating and support further prospective evaluation of risk-adapted adjuvant ALK-TKI therapy in stage I ALK-positive NSCLC.
- Publisher Full Text (DOI)
- TLS-related immune organization and regional IRF4 expression in pretreatment biopsies of advanced lung adenocarcinoma. [Journal Article]Lung Cancer. 2026 Nov; 221:109648.LC
- CONCLUSIONS: Biopsy-captured B-cell organization and regional IRF4 expression may provide complementary information on TLS-related immunity when comprehensive TLS characterization is limited by small-biopsy sampling.
- Publisher Full Text (DOI)
- Lung cytology in the diagnostic workflow: A real-world study of its clinical impact. [Journal Article]Lung Cancer. 2026 Nov; 221:109643.LC
- CONCLUSIONS: Cytological samples provided an independent diagnostic and predictive contribution in more than 20% of cases. It also supported histological findings in a further 43.7% of patients, making it clinically informative in nearly two-thirds of patients. Although its performance varied according to specimen type, combining multiple sampling strategies significantly improved diagnostic yield. These findings highlight the continued value of cytology and support its broader integration into contemporary lung cancer diagnostic algorithms.
- Publisher Full Text (DOI)
- Trial-specific absolute disease-free survival effects of postoperative PD-1/PD-L1 blockade after complete resection of NSCLC: A systematic review. [Systematic Review]Lung Cancer. 2026 Nov; 221:109642.LC
- CONCLUSIONS: Reconstructed trial-specific estimates suggest average absolute DFS gains through 36 months, with substantial uncertainty. They complement the original trial results when discussing postoperative treatment; they do not establish a class-wide effect, treatment ranking, or individual benefit.
- Publisher Full Text (DOI)
- Can We Extend Beyond 2 Years of Adjuvant ALK TKI Established by ALINA and ELEVATE in Resected Early Stage ALK+ NSCLC a Disease with High Predilection for CNS Metastasis with Novel Clinical Trial Designs? [Journal Article]
- The development and approval of three generations of ALK tyrosine kinase inhibitors (TKIs) since the identification of anaplastic lymphoma kinase fusions (ALK+) in NSCLC has led to improved survival especially with lorlatinib, the only third-generation ALK TKI in the metastatic incurable stage. The establishment of 3 years of adjuvant EGFR TKI in resected stage IB-IIIA EGFR+ NSCLC has led to impr…
- PMC Free PDF
- Exploratory analysis of extracellular vesicle Profile changes during pembrolizumab treatment in NSCLC. [Journal Article]Lung Cancer. 2026 Nov; 221:109640.LC
- CONCLUSIONS: Circulating EV proteomic analysis identified candidate biomarkers for pembrolizumab resistance and durable clinical benefit in advanced NSCLC.
- Publisher Full Text (DOI)
- Second-line therapy in extensive-stage small cell lung cancer: an unmet need highlighted by real-world evidence from the LALUCA registry. [Multicenter Study]Lung Cancer. 2026 Nov; 221:109639.LC
- CONCLUSIONS: This real-world analysis shows poor outcomes in patients with progressing ES-SCLC, reflected by both short median PFS and duration of second-line treatment, along with high rates of treatment discontinuation due to progression, highlighting the urgent need for more effective and tolerable treatment options.
- Publisher Full Text (DOI)
- Lung cancer after allogeneic hematopoietic stem cell transplantation. [Multicenter Study]Lung Cancer. 2026 Nov; 221:109633.LC
- CONCLUSIONS: In our study, ICI-based therapies were associated with prolonged survival in selected patients with advanced NSCLC and presumed host immune tolerance. We did not observe a clear signal of excess irAEs/GvHD. Our results support considering the use of ICIs in this population.
- Publisher Full Text (DOI)
- Systemic and intracranial activity of antibody-drug conjugates in patients with non-small cell lung cancer and brain metastases: A systematic review and meta-analysis. [Systematic Review]Lung Cancer. 2026 Nov; 221:109638.LC
- CONCLUSIONS: ADCs demonstrated clinically meaningful systemic and intracranial activity in patients with NSCLC and BM, with no significant difference in systemic ORR by BM status. These findings support ADCs as a promising therapeutic option for this underserved population.
- Publisher Full Text (DOI)
- Real-world progression-free survival with erlotinib versus osimertinib in EGFR L858R + T790M compound mutation non-small cell lung Cancer: An exploratory analysis of the MSK-CHORD dataset. [Journal Article]Lung Cancer. 2026 Nov; 221:109637.LC
- CONCLUSIONS: The expected osimertinib advantage was absent in L858R + T790M compound-mutant NSCLC. The opposing hazard ratio directions across mutation contexts (HR 1.29 vs 0.70), with a significant exploratory cross-cohort interaction (p = 0.007), suggest that the EGFR L858R + T790M compound mutation may represent a pharmacologically distinct entity with differential TKI sensitivity. These hypothesis-generating findings warrant prospective validation.
- Publisher Full Text (DOI)
- Concomitant medications and outcomes of bispecific T-cell engager therapy: A propensity-matched study of tarlatamab in ES-SCLC. [Journal Article]Lung Cancer. 2026 Nov; 221:109634.LC
- CONCLUSIONS: Several commonly used medications were associated with inferior survival in patients receiving tarlatamab for ES-SCLC. Although residual confounding cannot be excluded, these findings support prospective investigation of concomitant medication use during BiTE therapy.
- Publisher Full Text (DOI)
- Healing of Post-Operative Tracheal Disruption in a Patient with Thymic Carcinoma on Adjuvant Immunotherapy. [Case Reports]
- Pneumomediastinum from tracheal perforations due to primary repair breakdown can occur as a complication of thymic cancer surgery. Immunotherapy may be a viable adjuvant treatment for thymic carcinoma patients with tracheal perforations.
- PMC Free PDF
- Longitudinal transcriptomic profiling of paired early and metastatic EGFR-mutant lung adenocarcinomas reveals molecular programs associated with disease progression. [Journal Article]Lung Cancer. 2026 Nov; 221:109628.LC
- CONCLUSIONS: Longitudinal transcriptomic profiling of paired early-stage and metastatic EGFR-mutated LUAD revealed significant molecular reprogramming associated with disease progression. Metabolic adaptation, transport-related pathways, extracellular matrix remodeling, and coagulation-associated signaling were identified as key features of advanced disease. These progression-associated molecular programs showed prognostic relevance across independent transcriptomic and proteomic cohorts.
- Publisher Full Text (DOI)
- Pathological complete necrosis after pulmonary thermal ablation: a systematic review and meta-analysis of ablate-and-resect studies. [Systematic Review]Lung Cancer. 2026 Nov; 221:109631.LC
- CONCLUSIONS: Pathologic complete necrosis after pulmonary thermal ablation varies substantially across ablate-and-resect studies and is influenced by both treatment context and pathological assessment. The pooled estimate should therefore be interpreted as a descriptive summary of a heterogeneous evidence base rather than as a benchmark for contemporary definitive ablation.
- Publisher Full Text (DOI)
- More than a risk factor: alcohol use following diagnosis in non-small cell lung cancer patients. [Journal Article]Lung Cancer. 2026 Nov; 221:109635.LC
- CONCLUSIONS: This study provides the first longitudinal evidence on alcohol use following NSCLC diagnosis. Alcohol use declined substantially after diagnosis, but reductions were not sustained, underscoring the need for continued assessment throughout survivorship. Future studies are needed to understand the impact of post-diagnosis alcohol use on outcomes and develop evidence-based guidance for patient care.
- Publisher Full Text (DOI)